ASC Webinar Series: ASC’s Cell and Gene Therapy BioService Leverages its Stem Cell and Genome Editing Expertise to Advance Cell and Gene Therapy Program | ASC

Applied StemCell (ASC)’s webinar on Advancing gene and Cell Therapy Through iPSC and Genome Editing Technologies showcases our BioService CRO platform for advancing your gene and cell therapy programs.

Title: Advancing Gene and Cell Therapy Through iPSC and Genome Editing Technologies

Presenter: Ruby Yanru Chen-Tsai, PhD, CEO and President of Applied StemCell

Applied StemCell brings its several years of experience and expertise in genome editing and stem cell technologies to provide custom service to advance preclinical stage gene and cell therapy projects. From generating preclinical proof-of-concept cell line and animal models and assay development (AAV potency, efficacy and safety assessments), all the way to CMC consultation for vector and cell line manufacturing, Applied StemCell’s technology platforms will pave the way for a smooth screening of your cell and gene therapy candidates to enable IND-filing.

 

Topics covered in this webinar:

• Quality management and data security

• Focus areas in cell and gene therapy: preclinical, clinical and manufacturing

• ASC’s Core technology and positioning as a cell and gene therapy CRO

• Gene therapy and preclinical assay development capabilities: model generation, optimizing constructs, efficacy studies, AAV infectivity, AAV potency assay, toxicology studies, and stability

• iPSCs for assay development: patient-derived cells, iPSC gene editing, iPSC differentiation, drug efficacy and toxicity screening

• COVID 19 support: Humanized ACE2 mouse model for SARS-CoV2 research and therapeutic development

 

Webinar Audience: This webinar is ideal for audience involved in early projects in

• Gene therapy

• Cell-based therapy

• Regenerative medicine

• Biologics Drug Development

 

For more details on our BioService CRO platform, please explore our website or contact us at info@appliedstemcell.com.

 

About Applied StemCell, Inc.

Applied StemCell, Inc. (ASC) is a fast-growing Gene & Cell Therapy CRO headquartered in California, USA. ASC was founded in 2008 with a goal to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry. With more than 12 years of experience in genome editing and stem cell technologies, ASC is proud to develop innovative technology platforms offering services and products in the field of Stem Cells (iPSCs/ESCs, differentiated cells) and animal/cell models for disease modeling, antibody discovery & screening, bioproduction, AAV potency assays, cell therapy and regenerative medicine. Our Cell and Gene Therapy Bioservice platform also includes consultation for Pre-IND filing and CMC processes.

More information can be found at www.appliedstemcell.com.

 

Media Contact:

Maki Ogawa

Marketing Director, Applied StemCell, Inc.

408-773-8007

maki.ogawa@appliedstemcell.com

Google